Education
About Us
Working with TipRanks
Follow Us
Jaguar Animal Health (JAGX)
NASDAQ:JAGX
Top Page
Jaguar Animal Health
(NASDAQ:JAGX)
42Neutral
Jaguar Animal Health (JAGX) vs. S&P 500 (SPY)
Market Cap
$4.08M
Dividend YieldN/A
Average Volume (3M)591.08K
Price to Earnings (P/E)―
Beta (1Y)-0.27
Revenue Growth-2.25%
EPS Growth96.10%
CountryUS
Employees49
SectorHealthcare
Sector Strength76
IndustryBiotechnology
Share Statistics
EPS (TTM)-16.10
Shares Outstanding16,402,164
10 Day Avg. Volume1,023,964
30 Day Avg. Volume591,081
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.26
Price to Cash Flow (P/CF)-0.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Jaguar Animal Health Business Overview & Revenue Model
Company DescriptionJaguar Animal Health, operating under the ticker symbol JAGX, is a biotechnology company focused on the development and commercialization of gastrointestinal products for both human and animal health. The company operates in the pharmaceutical sector, with a particular emphasis on products that address unmet medical needs in the field of animal health. Jaguar Animal Health's core products are derived from natural plant compounds and are designed to provide sustainable health solutions for livestock and companion animals.
How the Company Makes MoneyJaguar Animal Health makes money through the sale and licensing of its proprietary pharmaceutical products, which are developed for the treatment of gastrointestinal conditions in animals. The company's revenue model primarily involves direct sales of its products to veterinary clinics, animal hospitals, and livestock producers. Additionally, Jaguar Animal Health may engage in strategic partnerships and licensing agreements with other pharmaceutical companies, which can provide upfront payments, milestone payments, and royalties on product sales. The company's earnings are significantly influenced by the successful development and commercialization of its product pipeline, regulatory approvals, and market adoption of its solutions in the animal health industry.
Jaguar Animal Health Financial Statement Overview
Summary
Jaguar Animal Health is experiencing revenue growth but faces significant profitability and liquidity challenges. The company struggles with substantial losses, a high debt-to-equity ratio, and negative cash flow.Income Statement
Jaguar Animal Health shows persistent revenue growth, with a TTM revenue of $10.48M, up from $9.76M in 2023. However, the company is struggling with profitability, evidenced by a negative net profit margin and significant EBIT and EBITDA losses. The gross profit margin remains healthy at approximately 68.6%, but the net loss indicates ongoing financial challenges.35
Negative
Balance Sheet
The balance sheet reveals a high debt-to-equity ratio and limited equity base, with stockholders' equity at $13.61M against $34.27M in total debt. The equity ratio stands at 23.3%, indicating financial leverage concerns. Despite these challenges, there is a noteworthy improvement in stockholders' equity from negative values in previous years.40
Negative
Cash Flow
The cash flow statement highlights negative operating cash flow and free cash flow, reflecting liquidity issues. The free cash flow growth rate is improving, but the company is still heavily reliant on financing activities. The operating cash flow to net income ratio is negative, emphasizing ongoing cash management challenges.30
Negative
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 10.48M | 9.76M | 11.96M | 4.33M | 9.38M | 5.78M | Gross Profit |
| 7.19M | 7.72M | 9.94M | 2.00M | 6.11M | 1.96M | EBIT |
| -29.86M | -34.29M | -34.41M | -39.07M | -21.30M | -24.95M | EBITDA |
| -29.92M | -33.13M | -33.38M | -42.35M | -28.74M | -30.87M | Net Income Common Stockholders |
| -37.74M | -41.30M | -47.45M | -60.25M | -36.79M | -38.54M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 2.57M | 6.47M | 5.47M | 17.05M | 8.09M | 3.50M | Total Assets |
| 41.04M | 50.76M | 47.45M | 53.27M | 42.84M | 36.41M | Total Debt |
| 16.08M | 37.09M | 34.84M | 29.36M | 16.21M | 7.57M | Net Debt |
| 13.52M | 30.63M | 29.37M | 12.31M | 8.12M | 4.07M | Total Liabilities |
| 35.66M | 45.87M | 48.81M | 41.41M | 25.64M | 25.74M | Stockholders Equity |
| 5.38M | 4.96M | -657.00K | 11.61M | 17.20M | 10.67M |
| Cash Flow | Free Cash Flow | ||||
| -29.01M | -33.24M | -34.78M | -34.98M | -15.29M | -20.46M | Operating Cash Flow |
| -29.01M | -33.24M | -33.10M | -34.97M | -15.28M | -20.46M | Investing Cash Flow |
| -10.00K | 0.00 | -1.68M | -6.00K | -7.00K | 0.00 | Financing Cash Flow |
| 39.02M | 34.23M | 23.18M | 43.94M | 19.49M | 21.77M |
Jaguar Animal Health Technical Analysis
Negative
0.23
Price Trends
0.73
Negative
0.88
Negative
1.48
Negative
Market Momentum
-0.14
Positive
20.36
Positive
7.63
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JAGX, the sentiment is Negative. The current price of 0.23 is below the 20-day moving average (MA) of 0.50, below the 50-day MA of 0.73, and below the 200-day MA of 1.48, indicating a bearish trend. The MACD of -0.14 indicates Positive momentum. The RSI at 20.36 is Positive, neither overbought nor oversold. The STOCH value of 7.63 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JAGX.
Jaguar Animal Health Risk Analysis
Jaguar Animal Health disclosed 65 risk factors in its most recent earnings report. Jaguar Animal Health reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Jaguar Animal Health Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | $73.06B | 29.85 | 50.91% | 1.10% | 8.33% | 7.70% | |
73 Outperform | $34.24B | 39.47 | 57.66% | ― | 6.46% | 5.82% | |
68 Neutral | $13.21B | 36.62 | 131.11% | ― | 4.11% | 3328.10% | |
65 Neutral | $5.23B | 15.52 | 5.49% | ― | 0.50% | ― | |
49 Neutral | $6.92B | 0.65 | -53.47% | 2.48% | 22.66% | 1.33% | |
42 Neutral | $4.08M | ― | -432.40% | ― | -2.25% | 96.10% |
* Healthcare Sector Average
Performance Comparison
JAGX
Jaguar Animal Health
0.23
-4.10
-94.69%
IDXX
Idexx Laboratories
420.99
-108.72
-20.52%
ZTS
Zoetis
163.03
-3.01
-1.81%
ELAN
Elanco Animal Health
10.53
-5.38
-33.82%
CHWY
Chewy
33.86
18.44
119.58%
Jaguar Animal Health Earnings Call Summary
Earnings Call Date: Nov 13, 2024 | % Change Since: -78.90% | Next Earnings Date: Apr 15, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted significant revenue growth and promising clinical trial results, particularly in the area of cancer treatment. However, the company's increased net loss and non-GAAP recurring EBITDA loss indicate financial challenges. The achievements in drug development and product launches suggest potential future growth, but financial improvements are necessary.Highlights
Revenue Growth
Net third quarter 2024 revenue was approximately $3.1 million, which represents a 14% increase over the second quarter of 2024 and an 11% increase over the third quarter of 2023.
Phase III OnTarget Trial Success
Significant results achieved in the Phase III OnTarget trial for breast cancer patients, with results accepted for presentation at the San Antonio Breast Cancer Symposium.
Gelclair Launch
Launch of FDA-approved oral mucositis prescription product, Gelclair, in the United States, aimed at managing cancer treatment-related side effects.
Orphan Drug Designations
Crofelemer received orphan drug designation in the United States and Europe for MVID and SBS-IF indications.
Lowlights
Net Loss Increase
Net loss attributable to common shareholders increased by approximately $2.1 million, from $7.8 million in Q3 2023 to $9.9 million in Q3 2024.
Non-GAAP Recurring EBITDA Loss
Non-GAAP recurring EBITDA for Q3 2024 showed a net loss of $9.2 million compared to a net loss of $6.2 million in Q3 2023.
Company Guidance
During the Q3 2024 earnings call for Jaguar Health, the company reported a net revenue of approximately $3.1 million, marking a 14% increase from Q2 2024 and an 11% increase from Q3 2023. The call highlighted the company's ongoing efforts in commercial and development initiatives, including the launch of their third FDA-approved prescription product, Gelclair, in the U.S. Additionally, significant results from the Phase III OnTarget trial in breast cancer patients will be presented at the San Antonio Breast Cancer Symposium. The company is also advancing clinical trials for crofelemer in rare disease indications such as microvillous inclusion disease (MVID) and short bowel syndrome with intestinal failure (SBS-IF), with Phase II trials expected to start in Q4 2024. Financially, the company's net loss from operations reduced from $8.8 million in Q3 2023 to $7.3 million in Q3 2024, while non-GAAP recurring EBITDA showed a loss of $9.2 million. The board has no intention of implementing a reverse stock split, focusing instead on upcoming catalysts and strategic developments.Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.